Eli Lilly and Company

Pfizer Corporation

William Thomas McMillen

Jason Scott Sawyer

Gaiying Zhao

Hong-Yu Li

Douglas Wade Beight

Takushi Kaneko

Sajan Joseph

James Robert Henry

Yan Wang

Michael J Rodriguez

Guillermo S Cortez

Johnathan Alexander McLean

Daniel Jon Sall

Jolie Anne Bastian

Edward C R Smith

Jose Eduardo Lopez

Alexander Glenn Godfrey

Jeffrey Daniel Cohen

Joshua Ryan Clayton

Ryan Edward Stites

Almudena Rubio

Jacqueline Mary Wurst

Jonathan Michael Yingling

Joyce Z Crich

Delu Jiang

Hong Hu

Takako Wilson

Melissa Kate Slater

Todd Vincent Decollo

Jiehao Chen

Adel Ahmed Rashad Ahmed

Bradley Earl Reaman

Timothy Paul Burkholder

David Andrew Coates

Theodore Goodson, Jr

Sushant Malhotra

Rosanne Bonjouklian

Jeremy Schulenburg York

Shawn Christopher Miller

Chi-Hsin Richard King

Thomas Albert Engler

Wei-Guo Su

Brian C Vanderplas

Junkai Liao

Brandon Lee Parkhurst

Craig Daniel Wolfangel

Clive Gideon Diefenbacher

Robert W McLaughlin

David H B Ripin

Huaxing Pei

Charles Raymond Heap

Sachin Govindlal Maniar

Hongjuan Zhao

Sreenivasa Reedy Mundla

The present invention provides a compound of Formula I:

Glucocorticoid receptor agonists

The present invention provides a compound of Formula I: wherein R is H or Ris H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF, Ris H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl;Ris NH, or CHNH; andX is O, OCH, OCHCH, OCH(CH), CHO, SCH, CHS, CH, NHCH, CHNH, N(CH)CH, CHCH, C&#x2261;C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.

The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

ERK inhibitors

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. 

1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

2,3-dihydro-1H-indole compounds

The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF&#x3b2;R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.

Aminopyridyloxypyrazole compounds

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Triazolyl aminopyrimidine compounds

The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds. 

Compounds as pharmaceutical agents

The disclosed invention is directed to compounds of the formula: Formula (I) and methods of using these compounds. 

Fused pyrazole derivatives as TGF-&#x3b2; signal transduction inhibitors for the treatment of fibrosis and neoplasms

Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

Pyrazolopyridine derivatives as pharmaceutical agents

Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S

Pyrrole derivatives as pharmaceutical agents

Ketolide antibiotics

Growing community of inventors

Indianapolis, IN, United States of America

William Thomas McMillen